Publications, posters, and abstracts

MVP staff and partners have been involved in the publication of scientific papers, and they regularly attend national and international conferences that address issues related to meningitis, epidemiology, and vaccine development. Some of the publications, posters, and/or abstracts not listed in our Research and Development section are listed below.

The PATH Vaccine Resource library provides additional information on meningococcal meningitis, meningococcal vaccines, epidemiology, and vaccine research.

Publications

Brooke S, Harner-Jay CM, Lasher H, Jacoby E. How public-private partnerships handle intellectual property: the PATH experience. In Krattiger A, Mahoney RT, Nelsen L, et al, eds. Intellectual Property Management in Health and Agricultural Innovation: A Handbook. Oxford, UK: MIHR; 2007:1755–1763. (pdf 261 kb).

Colombini A, Badolo O, Gessner B, Jaillard P, Seini E, Da Silva A. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine. 2011;29(33):5474–5480. View abstract.

Colombini A, Bationo F, Zongo S, et al. Costs for households and community perception of meningitis epidemics in Burkina Faso. Clinical Infectious Diseases. 2009;49(10):1520–1525. View abstract.

Findlow H, Plikaytis B, Aase A, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clinical and Vaccine Immunology. 2009;16(7):969–977. View abstract.

Findlow H, Sow S, Borrow R, et al. Meningococcal group C and w135 immunological hyporesponsiveness in African toddlers. Clinical and Vaccine Immunology. 2011;18(9):1492–1496. View abstract.

Foschiatti M, Hearshaw M, Cescutti P, Ravenscroft N, Rizzo R. Conformational studies of the capsular polysaccharide produced by Neisseria meningitidis group A. Carbohydrate Research. 2009;344(7):940–943. View abstract.

Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–3371. View abstract.

Jodar L, Feavers I, Salisbury D, Granoff D. Development of vaccines against meningococcal disease. Lancet. 2002;359(9316):1499–1508. View abstract.

Kieny M-P, LaForce M. The promise of conjugate vaccines for Africa. Vaccine. 2007;3(25) Suppl 1:A108–110. View abstract.

Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007; 3(25) Suppl 1:A101–107. View abstract.

LaForce FM, Konde K, Viviani S, Préziosi M-P. The Meningitis Vaccine Project. Vaccine. 2007;3(25) Suppl 1:A97–100. View abstract.

LaForce FM, Okwo-Bele JM. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Affairs. 2011;30(6):1049–1057. View abstract.

LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution. Vaccine. 2009;24(27) Suppl 2:B13–19. View abstract.

Lee C, Kuo W, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine. 2009; 27(5):726–732. View abstract.

Soriano-Gabarro M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: A demonstration project. Journal of Health, Population, and Nutrition. 2004;22(3):275–285. View abstract.

Sow S, Okoko B, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. New England Journal of Medicine. 2011; 364:2293–2304.

Thomson M, Molesworth A, Djingarey M, Yameogo K, Belanger F, Cuevas L. Potential of environmental models to predict meningitis epidemics in Africa. Tropical Medicine & International Health. 2006;11(6):781–788. View abstract.

World Health Organization (WHO). Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience (pdf 537 kb). Weekly Epidemiological Record. 2005;37(80):313–320.

World Health Organization (WHO). Managing meningitis epidemics in Africa. A quick reference guide for health authorities and health-care workers (pdf 337 kb). November 2010. WHO/HSE/GAR/ERI/2010.4.

World Health Organization (WHO). Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines. 2006;BS/06.2041 (pdf 442 kb).

World Health Organization (WHO). Standard operating procedures for enhanced meningitis surveillance in Africa. 2009. (pdf 211kb).

Posters

Badolo O, Tiendrebeogo E, Novak R, et al. Surveillance of meningococcal disease in Burkina Faso. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P234 (pdf 4.21 mb).

Caugant D, Tamboura B, Tapia M, et al. Lessons from meningococcal carriage studies in West Africa. Poster presented at: 10th European Monitoring Group for Meningococci meeting, 17–19 June 2009; Manchester, United Kingdom. (pdf 131 kb).

Caugant D, Tamboura B, Tapia M, et al. Carriage of Neisseria meningitidis in 2–29 years old in Mali, Senegal, and The Gambia. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P168 (pdf 4.21 mb).

Colombini A, Badolo O, Jaillard P, et al. Socioeconomic study of meningitis epidemic impact in Burkina Faso. 2011 (pdf 124 kb).

Djingarey M, Noazin S, Préziosi MP, et al. A 20-year retrospective analysis of epidemic meningitis surveillance data in Burkina Faso, Mali, and Niger. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P166 (pdf 4.21 mb).

Djingarey M, Perea W, Bertherat E, et al. Implementation of standard operating procedures for enhanced meningitis surveillance in 13 countries of the African meningitis belt from 2003 to 2008. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P231 (pdf 4.21 mb).

Findlow H, Borrow R, Sow S, et al. Meningococcal serogroup C and W135 immunological hyporesponsiveness in African toddlers. Poster presented at: 10th European Monitoring Group for Meningococci meeting, 17–19 June 2009; Manchester, United Kingdom. (pdf 4.02 mb).

LaForce M. Nearing success: The development of an affordable group A meningococcal conjugate vaccine to eliminate epidemic meningitis from Africa. Oral presentation at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. O62 (pdf 4.21 mb).

Ravenscroft N, Hearshaw M, Martino A, et al. Physicochemical and immunological characterization of the drug product (final lot) of a meningococcal group A conjugate vaccine. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P101 (pdf 4.21 mb).

MVP documents

LaForce M. Introduction of a group A meningococcal conjugate
vaccine in sub-Saharan Africa: Cost/savings analysis. MVP unpublished data. 2008. (pdf 623 kb).